标签归档：sc

FEN1-IN-SC13

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FEN1-IN-SC13 

FEN1-IN-SC13 是一种有效的 DNA 片段化核酸内切酶 1 (FEN1) 抑制剂 (CN106692155A, SC13)。

FEN1-IN-SC13

FEN1-IN-SC13 Chemical Structure

CAS No. : 2098776-03-3

规格 价格 是否有货 数量
5 mg ￥2500 In-stock
10 mg ￥3900 In-stock
25 mg ￥7800 In-stock
50 mg ￥12500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

FEN1-IN-SC13 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library

生物活性

FEN1-IN-SC13 is a potent DNA fragmentation endonuclease 1 (FEN1) inhibitor (CN106692155A, SC13)[1].

分子量

433.52

Formula

C24H23N3O3S
CAS 号

2098776-03-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 62.5 mg/mL (144.17 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3067 mL 11.5335 mL 23.0670 mL
5 mM 0.4613 mL 2.3067 mL 4.6134 mL
10 mM 0.2307 mL 1.1533 mL 2.3067 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Application of small-molecular inhibitor SC13 targeting to FEN1 and derivative of small-molecular inhibitor SC13 in preparing tumor treatment medicine. CN106692155A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

FEN1-IN-SC13

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FEN1-IN-SC13 

FEN1-IN-SC13 是一种有效的 DNA 片段化核酸内切酶 1 (FEN1) 抑制剂 (CN106692155A, SC13)。

FEN1-IN-SC13

FEN1-IN-SC13 Chemical Structure

CAS No. : 2098776-03-3

规格 价格 是否有货 数量
5 mg ￥2500 In-stock
10 mg ￥3900 In-stock
25 mg ￥7800 In-stock
50 mg ￥12500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

FEN1-IN-SC13 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library

生物活性

FEN1-IN-SC13 is a potent DNA fragmentation endonuclease 1 (FEN1) inhibitor (CN106692155A, SC13)[1].

分子量

433.52

Formula

C24H23N3O3S
CAS 号

2098776-03-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 62.5 mg/mL (144.17 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3067 mL 11.5335 mL 23.0670 mL
5 mM 0.4613 mL 2.3067 mL 4.6134 mL
10 mM 0.2307 mL 1.1533 mL 2.3067 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Application of small-molecular inhibitor SC13 targeting to FEN1 and derivative of small-molecular inhibitor SC13 in preparing tumor treatment medicine. CN106692155A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

FEN1-IN-SC13

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FEN1-IN-SC13 

FEN1-IN-SC13 是一种有效的 DNA 片段化核酸内切酶 1 (FEN1) 抑制剂 (CN106692155A, SC13)。

FEN1-IN-SC13

FEN1-IN-SC13 Chemical Structure

CAS No. : 2098776-03-3

规格 价格 是否有货 数量
5 mg ￥2500 In-stock
10 mg ￥3900 In-stock
25 mg ￥7800 In-stock
50 mg ￥12500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

FEN1-IN-SC13 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library

生物活性

FEN1-IN-SC13 is a potent DNA fragmentation endonuclease 1 (FEN1) inhibitor (CN106692155A, SC13)[1].

分子量

433.52

Formula

C24H23N3O3S
CAS 号

2098776-03-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 62.5 mg/mL (144.17 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3067 mL 11.5335 mL 23.0670 mL
5 mM 0.4613 mL 2.3067 mL 4.6134 mL
10 mM 0.2307 mL 1.1533 mL 2.3067 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Application of small-molecular inhibitor SC13 targeting to FEN1 and derivative of small-molecular inhibitor SC13 in preparing tumor treatment medicine. CN106692155A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

多肽定制Sarafotoxin S6c 编码 [121695-87-2]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Sarafotoxin S6c
编码 [121695-87-2]
别名 Sarafotoxin S6c
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） CTCNDMTDEECLNFCHQDVIW[Cys1-Cys15, Cys3-Cys11 bridge]
序列（三字母缩写） Cys-Thr-Cys-Asn-Asp-Met-Thr-Asp-Glu-Glu-Cys-Leu-Asn-Phe-Cys-His-Gln-Asp-Val-Ile-Trp(Cys1-Cys15, Cys3-Cys11 bridge)
基本描述
溶解度
分子量 2515.8
化学式 C103H147N27O37S5
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Sarafotoxin S6c 编码 [121695-87-2]
Figures Sarafotoxin S6c 编码 [121695-87-2]
Reference
C端
N端
化学桥 (Cys1-Cys15, Cys3-Cys11 bridge)

4SC-203

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

4SC-203 

4SC-203 是一种有效的多激酶 (multikinase) 抑制剂，具有潜在的抗肿瘤活性。4SC-203 选择性抑制 FLT3/STK1, FLT3 突变型，VEGFRs。

4SC-203

4SC-203 Chemical Structure

CAS No. : 895533-09-2

规格 价格 是否有货 数量
5 mg ￥2500 In-stock
10 mg ￥4000 In-stock
25 mg ￥8500 In-stock
50 mg ￥13500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

4SC-203 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs[1].

分子量

642.77

Formula

C33H38N8O4S
CAS 号

895533-09-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (194.47 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5558 mL 7.7788 mL 15.5577 mL
5 mM 0.3112 mL 1.5558 mL 3.1115 mL
10 mM 0.1556 mL 0.7779 mL 1.5558 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

4SC-203

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

4SC-203 

4SC-203 是一种有效的多激酶 (multikinase) 抑制剂，具有潜在的抗肿瘤活性。4SC-203 选择性抑制 FLT3/STK1, FLT3 突变型，VEGFRs。

4SC-203

4SC-203 Chemical Structure

CAS No. : 895533-09-2

规格 价格 是否有货 数量
5 mg ￥2500 In-stock
10 mg ￥4000 In-stock
25 mg ￥8500 In-stock
50 mg ￥13500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

4SC-203 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs[1].

分子量

642.77

Formula

C33H38N8O4S
CAS 号

895533-09-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (194.47 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5558 mL 7.7788 mL 15.5577 mL
5 mM 0.3112 mL 1.5558 mL 3.1115 mL
10 mM 0.1556 mL 0.7779 mL 1.5558 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

4SC-203

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

4SC-203 

4SC-203 是一种有效的多激酶 (multikinase) 抑制剂，具有潜在的抗肿瘤活性。4SC-203 选择性抑制 FLT3/STK1, FLT3 突变型，VEGFRs。

4SC-203

4SC-203 Chemical Structure

CAS No. : 895533-09-2

规格 价格 是否有货 数量
5 mg ￥2500 In-stock
10 mg ￥4000 In-stock
25 mg ￥8500 In-stock
50 mg ￥13500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

4SC-203 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs[1].

分子量

642.77

Formula

C33H38N8O4S
CAS 号

895533-09-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (194.47 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5558 mL 7.7788 mL 15.5577 mL
5 mM 0.3112 mL 1.5558 mL 3.1115 mL
10 mM 0.1556 mL 0.7779 mL 1.5558 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.24 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Spironolactone-d3-1(Synonyms: SC9420-d3-1)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Spironolactone-d3-1 (Synonyms: SC9420-d3-1)

Spironolactone-d3-1 是 Spironolactone 氘代物。Spironolactone (SC9420) 是一种具有口服活性醛固酮盐皮质激素受体 (aldosterone mineralocorticoid receptor) 拮抗剂，IC50 值为 24 nM。Spironolactone 也是雄激素受体 (androgen receptor) 拮抗剂，IC50 为 77 nM。Spironolactone 促进足细胞自噬 (autophagy)。

Spironolactone-d3-1(Synonyms: SC9420-d3-1)

Spironolactone-d3-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Spironolactone-d3-1 is deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

419.59

Formula

C24H29D3O4S
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Kim GK, et al. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012;5(3):37-50.

    [3]. Fagart J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932-29940.

    [4]. Dong D, et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int Urol Nephrol. 2019;51(4):755-764.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SC-VC-PAB-DM1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SC-VC-PAB-DM1 

SC-VC-PAB-DM1 是具有抗癌活性的抗体偶联药物的一部分。由有效的微管蛋白抑制剂 DM1 和 ADC linker SC-VC-PAB 连接而成。

SC-VC-PAB-DM1

SC-VC-PAB-DM1 Chemical Structure

CAS No. : 2259318-47-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SC-VC-PAB-DM1 is a drug-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB[1].

分子量

1280.81

Formula

C61H82ClN9O19
CAS 号

2259318-47-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. LANNUTTI, Brian, et al. ROR1 ANTIBODY IMMUNOCONJUGATES. WO 2018/237335 Al.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SC79

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SC79  纯度: ≥98.0%

SC79，一个特异的、能透过血脑屏障的 Akt 激动剂，可激活胞质中 Akt，并抑制 Akt 膜转位。SC79 特异性结合Akt 的PH 结构域。

SC79

SC79 Chemical Structure

CAS No. : 305834-79-1

规格 价格 是否有货 数量
5 mg ￥600 In-stock
10 mg ￥950 In-stock
50 mg ￥2820 In-stock
100 mg ￥4200 In-stock
200 mg ￥5700 In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

SC79 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus

生物活性

SC79, a unique specific and BBB permeable Akt activator, activates Akt in the cytosol and inhibits Akt membrane translocation. SC79 specifically binds to the PH domain of Akt[1][2][3].

IC50 & Target

Akt

 

体外研究
(In Vitro)

SC79 augmentes Akt phosphorylation at both the Thr308 and S473 sites[1].
SC79 (10.96 μM) induces cytosolic phosphorylation of Akt. SC79 enhances IGF1-induced Akt phosphorylation in both serum-starved cells and cells grown in serum-rich medium[1].
SC79 reduces neuronal excitotoxicity and prevents stroke-induced neuronal death. SC79 suppresses PHAKTM-GFP plasma membrane translocation[1].
SC79 restores proliferation of BRAT1 knockdown cells, and reduces the production of superoxide in mitochondria of MitoSox positive cells[2].
SC79 upregulates FLIPL/S expression and consequently suppresses caspase-8 activation[5].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: HeLa cells.
Concentration: 4 μg/mL (10.96 μM).
Incubation Time: 30 min.
Result: Induced cytosolic phosphorylation of Akt.

体内研究
(In Vivo)

SC79 treatment, even at much high dose (0.4 mg/g of body weight), does not induce any detectable changes in body weight, survival rate, appearance, and behavior in mice[1].
SC79 (10 mg/kg, i.p.) Protects C57BL/6 mice from fas-induced fulminant hepatic failure[4].
SC79 protects hepatocytes from TNFα-mediated apoptosis and mice from Gal/LPS-induced liver injury and damage[5].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male, age-matched (6- to 8-weekeold) C57BL/6 or BALB/c mice weighing 16 to 18 g[4].
Dosage: 10 mg/kg.
Administration: Intraperitoneally at 0.5 hour before the i.p. administration of an agonistic anti-Fas Jo2 antibody at a lethal dose of 0.5 and 0.4 mg/kg for C57BL/6 and BALB/c mice, respectively.
Result: Treatment of mice with 10 mg/kg of SC79 at 0.5 hour before Jo2 injection increased mouse survival at 12 hours after Jo2 injection from 0% to 35%, and no additional mortality was observed to the end of the 2-month observation period.
Animal Model: Male, age-matched (6 to 8 weeks old) C57BL/6 mice weighing 16-18 g[5].
Dosage: 10 mg/kg.
Administration: Intraperitoneally at 0.5 h before i.p. administration of 400 mg/kg of D-galactosamine (D-Gal) and 60 µg/kg of lipopolysaccharide (LPS) for C57BL/6 mice.
Result: Gal/LPS challenge there was more bleeding on the liver of the vehicle control-treated mice as compared to that of SC79-treated mice.
A single dose of SC79 significantly reduced Gal/LPS-mediated liver damage but not an infiltration of inflammatory cells in liver sections.

分子量

364.78

Formula

C17H17ClN2O5
CAS 号

305834-79-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (274.14 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7414 mL 13.7069 mL 27.4138 mL
5 mM 0.5483 mL 2.7414 mL 5.4828 mL
10 mM 0.2741 mL 1.3707 mL 2.7414 mL

*

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 10 mg/mL (27.41 mM); Suspended solution; Need ultrasonic

    此方案可获得 10 mg/mL (27.41 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 100.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: 5 mg/mL (13.71 mM); Suspended solution; Need ultrasonic

  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.85 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.85 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Jo H, et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10581-10586.

    [2]. So EY, et al. BRAT1 deficiency causes increased glucose metabolism and mitochondrial malfunction. BMC Cancer. 2014 Jul 29;14:548

    [3]. Liu X, et al. Activation of Akt by SC79 decreased cerebral infarct in early cerebral ischemia-reperfusion despite increased BBB disruption. Neurosci Lett. 2018 Aug 10;681:78-82.

    [4]. Liu W, et al. A Novel AKT Activator, SC79, Prevents Acute Hepatic Failure Induced by Fas-Mediated Apoptosis of Hepatocytes. Am J Pathol. 2018 May;188(5):1171-1182.

    [5]. Jing ZT, et al. AKT activator SC79 protects hepatocytes from TNF-α-mediated apoptosis and alleviates d-Gal/LPS-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2019 Mar 1;316(3):G387-G396.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SC144

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SC144  纯度: 98.60%

SC144 是首创的口服活性 gp130 (IL6-beta) 抑制剂。SC144 结合 gp130，诱导 gp130 磷酸化(S782) 和去糖基化，消除 Stat3 磷酸化和核易位，进一步抑制下游靶基因的表达。SC144 对 gp130 配体触发的信号转导有明显的抑制作用。SC144 诱导人卵巢癌细胞凋亡。

SC144

SC144 Chemical Structure

CAS No. : 895158-95-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥990 In-stock
5 mg ￥900 In-stock
10 mg ￥1300 In-stock
25 mg ￥2400 In-stock
50 mg ￥4080 In-stock
100 mg ￥6950 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SC144 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Anti-Cancer Compound Library
  • Differentiation Inducing Compound Library
  • Orally Active Compound Library
  • Angiogenesis Related Compound Library
  • Targeted Diversity Library

生物活性

SC144 is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 shows potent inhibition of gp130 ligand-triggered signaling. SC144 induces apoptosis in human ovarian cancer cells[1].

IC50 & Target[1]

IL6-beta

 

体外研究
(In Vitro)

SC144 inhibits cell growth in a panel of human ovarian cancer cell lines with IC50s in a submicromolar range (IC50=OVCAR-8, OVCAR-5, OVCAR-3= 0.72, 0.49, 0.95 μM)[1].
The potency of SC144 toward NCI/ADR-RES (Paclitaxel- and Doxorubicin-resistant, IC50=0.43 μM) and HEY (Cisplatin-resistant, IC50=0.88 μM) suggests an ability to overcome drug resistance in ovarian cancer[1].
SC144 (2 μM; 24 hours) causes significantly more apoptosis in OVCAR-8 and Caov-3 than normal kidney epithelial and normal endometrial cells[1].
SC144 (0.5-2 μM; 0-6 hours) substantially increases the phosphorylation of gp130 (S782) in both OVCAR-8 and Caov-3 cells in a time- and dose-dependent manner[1].
SC144 is cytotoxic to ovarian cancer cells via a mechanism involving the inhibition of gp130 activity, leading to the inactivation of Akt and Stat3 as well as the suppression of Stat3-regulated gene expression. As are result, SC144 treatment eventually causes cell-cycle arrest, anti-angiogenesis, and apoptosis[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: OVCAR-8 and Caov-3 cells
Concentration: 2 μM
Incubation Time: 24 hours
Result: Significantly caused cell death in OVCAR-8 and Caov-3 cells.

Western Blot Analysis[1]

Cell Line: OVCAR-8, Caov-3 cells
Concentration: 0.5-2 μM
Incubation Time: 0-6 hours
Result: Substantially increased the phosphorylation of gp130 (S782) in both OVCAR-8 and Caov-3 cellsin a time- and dose-dependent manner.

体内研究
(In Vivo)

SC144 (10 mg/kg; i.p.; daily for 58 days) suppresses tumor growth in human ovariancancer xenografts[1].
SC144 (100 mg/kg;p.o.; daily for 35 days) treatment shows the average tumor volume in mice 82% smaller than that in the control group[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic mice (human ovarian cancer xenograft)[1]
Dosage: 10 mg/kg
Administration: I.p; daily for 58 days
Result: Significantly inhibited tumor growth by about 73%.

分子量

322.30

Formula

C16H11FN6O
CAS 号

895158-95-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 16.67 mg/mL (51.72 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1027 mL 15.5135 mL 31.0270 mL
5 mM 0.6205 mL 3.1027 mL 6.2054 mL
10 mM 0.3103 mL 1.5513 mL 3.1027 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Xu S, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther. 2013 Jun;12(6):937-49.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

宁波新芝 数控超级恒湿水(油)槽SC-25B

发表于由

宁波新芝 数控超级恒湿水(油)槽SC-25B

  • 品牌 新芝|SCIENTZ
  • 型号 SC-25B
  • 商品详情

    产品说明

    SC系列数控超级恒温水槽采用微机智能控制系统，设有循环泵,可把槽内被恒温液体外引,建立第二恒温场。

    广泛用于石油、化工、电子仪表、物理、化学、生物工程、医药卫生、生命科学、轻工食品

    物性测试及化学分析等研究部门、高等院校、企业质检及生产部门，为用户工作时提供一个冷热受控，温度均匀恒定的液体环境。

    产品特征

    1、数显分辨率：0.1℃

    2、温度波动度：±0.05℃～±0.2℃

    3、具有断电保护功能，可自动延时三分钟

    4、LED双窗口红绿双色数显

    5、具有循环泵，可建立机外第二恒温场

    6、具有自整定智能PID自动调节控制功能

    7、温度测量值偏差可修正，范围：±0.1℃～±20℃

    8、上下限温度报警可设定

    9、内胆采用优质不锈钢材料

     

    技术参数

    型号

    SC-25B

    温度范围℃

    室温+5～200

    温度波动度℃

    ±0.05～±0.2

    数显分辨率(mm³)

    0.1

    工作槽容积(mm³)

    280*250*300

    槽深度(mm)

    300

    循环泵流（L/min)

    6

    工作槽开口(mm²)

    235*160

    排水口

    无

    • Domatinostat(Synonyms: 4SC-202 free base)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Domatinostat (Synonyms: 4SC-202 free base) 纯度: 99.08%

    Domatinostat (4SC-202 free base) 是一种 I 型 HDAC 抑制剂，能够抑制 HDAC1，HDAC2，和 HDAC3 的活性，IC50 值分别为 1.20 μM，1.12 μM 和 0.57 μM；同时能够抑制组蛋白赖氨酸特异性脱甲基酶1 (Lysine specific demethylase 1) 的活性。

    Domatinostat(Synonyms: 4SC-202 free base)

    Domatinostat Chemical Structure

    CAS No. : 910462-43-0

    规格 价格 是否有货 数量
    Free Sample (0.1-0.5 mg)   Apply now  
    10 mM * 1 mL in DMSO ￥1181 In-stock
    2 mg ￥800 In-stock
    5 mg ￥1200 In-stock
    10 mg ￥1800 In-stock
    50 mg ￥5100 In-stock
    100 mg ￥8150 In-stock
    200 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Domatinostat 相关产品

    •相关化合物库:

    • Covalent Screening Library Plus
    • Drug Repurposing Compound Library Plus
    • Clinical Compound Library Plus
    • Bioactive Compound Library Plus
    • Apoptosis Compound Library
    • Cell Cycle/DNA Damage Compound Library
    • Epigenetics Compound Library
    • Histone Modification Research Compound Library
    • Anti-Cancer Compound Library
    • Clinical Compound Library
    • Anti-Aging Compound Library
    • Drug Repurposing Compound Library
    • Covalent Screening Library
    • Reprogramming Compound Library
    • Oxygen Sensing Compound Library
    • Anti-COVID-19 Compound Library
    • Anti-Breast Cancer Compound Library
    • Anti-Pancreatic Cancer Compound Library
    • Anti-Blood Cancer Compound Library
    • Anti-Liver Cancer Compound Library

    生物活性

    Domatinostat (4SC-202 free base) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).

    IC50 & Target[4]

    HDAC-3

    0.57 μM (IC50)

    HDAC-2

    1.12 μM (IC50)

    HDAC-1

    1.2 μM (IC50)

    HDAC-11

    9.7 μM (IC50)

    HDAC-5

    11.3 μM (IC50)

    HDAC-10

    21 μM (IC50)

    HDAC-9

    50 μM (IC50)

    体外研究
    (In Vitro)

    Domatinostat (4SC-202 free base) tosylate significantly reduces proliferation of all epithelial and mesenchymal UC cell lines (IC50 0.15-0.51 μM), inhibits clonogenic growth and induces caspase activity[1]. Domatinostat (4SC-202 free base) tosylate provokes apoptosis activation in CRC cells, while caspase inhibitors (z-VAD-CHO and z-DVED-CHO) significantly alleviate Domatinostat (4SC-202 free base) tosylate-exerted cytotoxicity in CRC cells. Meanwhile, Domatinostat (4SC-202 free base) tosylate induces dramatic G2-M arrest in CRC cells. Further studies show that AKT activation might be an important resistance factor of Domatinostat tosylate. Domatinostat (4SC-202 free base) tosylate-induced cytotoxicity is dramatically potentiated with serum starvation, AKT inhibition (by perifosine or MK-2206), or AKT1-shRNA knockdown in CRC cells. On the other hand, exogenous expression of constitutively active AKT1 (CA-AKT1) decreases the sensitivity by Domatinostat tosylate in HT-29 cells. Notably, Domatinostat (4SC-202 free base) tosylate, at a low concentration, enhances oxaliplatin-induced in vitro anti-CRC activity[2]. Domatinostat (4SC-202 free base) tosylate treatment induces potent cytotoxic and proliferation-inhibitory activities against established HCC cell lines (HepG2, HepB3, SMMC-7721) and patient-derived primary HCC cells. Domatinostat (4SC-202 free base) tosylate induces apoptosis signal-regulating kinase 1 (ASK1) activation, causing it translocation to mitochondria and physical association with Cyp-D[3].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    Oral gavage of Domatinostat (4SC-202 free base) inhibits HT-29 xenograft growth in nude mice, and when combined with oxaliplatin, its activity is further strengthened[2].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial

    分子量

    447.51

    Formula

    C23H21N5O3S
    CAS 号

    910462-43-0
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    In Vitro: 

    DMSO : ≥ 58 mg/mL (129.61 mM)

    * “≥” means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.2346 mL 11.1729 mL 22.3459 mL
    5 mM 0.4469 mL 2.2346 mL 4.4692 mL
    10 mM 0.2235 mL 1.1173 mL 2.2346 mL

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (5.59 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (5.59 mM，饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

      将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

    • 2.

      请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (5.59 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (5.59 mM，饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

      将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
    *以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
    参考文献

    • [1]. Pinkerneil M, et al. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. Target Oncol. 2016 Dec;11(6):783-798.

      [2]. Zhijun H, et al. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumour Biol. 2016 Aug;37(8):10257-67.

      [3]. Fu M, et al. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2016 Mar 4;471(2):267-73

      [4]. S.W.Henning, et al. Preclinical characterization of 4SC-202, a noval isotype specific HDAC inhibitor.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    SC-514(Synonyms: GK 01140)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    SC-514 (Synonyms: GK 01140) 纯度: 99.88%

    SC-514 是一种选择性 IKK-2 抑制剂 (IC50=11.2 μM)，不抑制其他 IKK 亚型或其他丝氨酸-苏氨酸和酪氨酸激酶。

    SC-514(Synonyms: GK 01140)

    SC-514 Chemical Structure

    CAS No. : 354812-17-2

    规格 价格 是否有货 数量
    10 mM * 1 mL in DMSO ￥610 In-stock
    10 mg ￥550 In-stock
    50 mg ￥1300 In-stock
    100 mg ￥2000 In-stock
    200 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    SC-514 相关产品

    •相关化合物库:

    • Bioactive Compound Library Plus
    • Immunology/Inflammation Compound Library
    • Kinase Inhibitor Library
    • NF-κB Signaling Compound Library
    • Stem Cell Signaling Compound Library
    • Anti-Cancer Compound Library
    • Anti-Aging Compound Library
    • Differentiation Inducing Compound Library
    • Pyroptosis Compound Library
    • Targeted Diversity Library
    • Anti-Liver Cancer Compound Library

    生物活性

    SC-514 is a selective IKK-2 inhibitor (IC50=11.2 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.

    IC50 & Target[1]

    IKK-2

    11.2 μM (IC50)

    CDK2/A

    61 μM (IC50)

    AUR2

    71 μM (IC50)

    PRAK

    75 μM (IC50)

    MSK

    123 μM (IC50)

    体外研究
    (In Vitro)

    SC-514 inhibits the native IKK complex or recombinant human IKK-1/IKK-2 heterodimer with IC50s of 6.1±2.2 μM and 2.7±0.7 μM, respectively. IKK-2 inhibition by SC-514 is selective, reversible, and competitive with ATP. SC-514 inhibits transcription of NF-κB-dependent genes in IL-1β-induced rheumatoid arthritis-derived synovial fibroblasts in a dose-dependent manner. SC-514 inhibits all forms of recombinant human IKK-2 including rhIKK-2 homodimer, rhIKK-1/rhIKK-2 heterodimer, as well as the constitutively active form of rhIKK-2 with comparable IC50 values in the 3-12 μM range[1]. To evaluate whether the reactive oxygen species (ROS)-inducing IKKβ inhibitor increases the sensitivity of melanoma cells to nitrosourea. The responses of melanoma cells are first assessed to SC-514/Fotemustine co-treatment. Melanoma cell lines are treated with 50 µM of SC-514 and Fotemustine alone and in combination for 48 h and growth inhibition is assessed. Co-treatment with SC-514 significantly enhances Fotemustine-induced cytotoxicity in all melanoma cell lines tested[2].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    SC-514 is efficacious in an acute model of inflammation, namely LPS-induced serum TNFα production in the rat. SC-514 shows a dose-dependent inhibition of TNFα production, validating IKK-2 as a potential anti-inflammatory drug target in vivo[1]. To obtain in vivo evidence for the implication of SC-514 in the response of cancer cells to Fotemustine, the xenograft mouse model of melanoma is used. Nude mice engrafted with A375 or G361 tumors are treated with vehicle control and 25 mg/kg SC-514 and/or 25 mg/kg Fotemustine daily for 13-15 consecutive days and the tumor behavior is monitored. Fotemustine treatment with SC-514 shows a clear combined effect and reduces the size of tumors in mice[2].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    224.30

    Formula

    C9H8N2OS2
    CAS 号

    354812-17-2
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    In Vitro: 

    DMSO : 100 mg/mL (445.83 mM; Need ultrasonic)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 4.4583 mL 22.2916 mL 44.5831 mL
    5 mM 0.8917 mL 4.4583 mL 8.9166 mL
    10 mM 0.4458 mL 2.2292 mL 4.4583 mL

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
    参考文献

    • [1]. Kishore N, et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem. 2003 Aug 29;278(35):32861-71.

      [2]. Tse AK, et al. Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biol. 2017 Apr;11:562-576.
    Kinase Assay
    [1]

    IKK complexes are immunoprecipitated from IL-1β-treated RASF cell lysates (0.5-2 mg) using a NEMO antibody (3-10 μg) followed by the addition of protein A-agarose beads. Antibody complexes are pelleted by centrifugation and washed 3 times with 1 mL of cold whole-cell lysis buffer followed by 2 washes in kinase buffer (25 mM HEPES, pH 7.6, 2 mM MgCl2, 2 mM MnCl2, 10 mM NaF, 5 mM DTT, and 1 mM phenylmethylsulfonyl fluoride). 100-200 μg of immunoprecipitated IKK is analyzed for kinase activity in a reaction containing 10 μM biotinylated IκBα peptide as substrate and 1 μM [γ-33P]ATP (2500 Ci/mmol). After incubation at room temperature for 30 min, 25 μL of the reaction mixture is withdrawn and added to a SAM 96 biotin capture plate. After successive wash steps the plate was allowed to air-dry, and 25 μL of scintillation fluid is added to each well. Incorporation of [γ-33P]ATP is measured using a Top-Count NXT[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    Cell Assay
    [2]

    For crystal violet staining assay, melanoma cell lines (1×104) are seeded in 60 mm dishes, and then untreated or pretreated with SC-514 (50 µM) and/or Fotemustine. Then, cells are formalin-fixed and stained with crystal violet. Cell numbers are measured as the optical density at 595 nm (OD595) of solubilized crystal violet from formalin-fixed cells. Cytotoxicity are also determined by the MTT reduction assay[2].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1][2]

    Rats[1]
    SC-514 or vehicle (2% Me2SO in saline) is administered either by oral gavage (50 mg/kg) or intraperitoneally (10 and 50 mg/kg) to adult male Wistar rats that have been deprived of food overnight. Two hours after compound treatment, 1 mg/kg LPS (Escherichia coli) in saline is administered intraperitoneally 90 min after LPS administration; the animals are bled and serum TNFα levels analyzed by a rat-specific TNFα ELISA.
    Mice[2]
    Male nu/nu BALB/c mice (6 weeks old) are maintained in individual ventilated cages. A375 or G361 (5×106) cells are resuspended in 0.1 mL PBS and inoculated subcutaneously into the backs of nude mice and allowed to grow for 7 days. After that, mice are randomly assigned to 4 groups (n=6 for each group) and treated by intraperitoneal injection with 200 µL 30% PEG/5% Tween-80 solution as the vehicle control and 25 mg/kg SC-514 and/or 25 mg/kg Fotemustine daily for 13-15 consecutive days. Body weight and tumor volume are measured every 3 days. Tumor volumes are determined by a caliper and calculated. At the end of the experiment, mice are sacrificed and tumor xenografts are collected. Tumor tissues are stored at -80°C for Western blot analysis.

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    • [1]. Kishore N, et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem. 2003 Aug 29;278(35):32861-71.

      [2]. Tse AK, et al. Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biol. 2017 Apr;11:562-576.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Cas(2147-61-7), 3-羟基-DL-犬尿素, ,3-Hydroxy-<SC>DL</SC>-kynurenine,

    发表于由

    3-羟基-DL-犬尿素

    98%

    有货

    Cas(2147-61-7), 3-羟基-DL-犬尿素, &#x20;,3-Hydroxy-&lt;SC&gt;DL&lt;/SC&gt;-kynurenine,

    货号 (SKU) 包装规格 是否现货 价格 数量
    H168592-25mg 25mg 期货 Cas(2147-61-7), 3-羟基-DL-犬尿素, &#x20;,3-Hydroxy-&lt;SC&gt;DL&lt;/SC&gt;-kynurenine,  
    H168592-100mg 100mg 期货 Cas(2147-61-7), 3-羟基-DL-犬尿素, &#x20;,3-Hydroxy-&lt;SC&gt;DL&lt;/SC&gt;-kynurenine,  
    H168592-250mg 250mg 现货 Cas(2147-61-7), 3-羟基-DL-犬尿素, &#x20;,3-Hydroxy-&lt;SC&gt;DL&lt;/SC&gt;-kynurenine,  

    基本信息

    产品名称 3-羟基-DL-犬尿素
    英文名称 3-Hydroxy-DL-kynurenine
    规格或纯度 98%
    运输条件 超低温冰袋运输

    相关属性

    CAS编号 2147-61-7
    敏感性 易吸潮
    熔点 >195°C
    溶解性 DMSO (Slightly, Heated), Methanol (Slightly, Heated), Water (Slightly, Heated)
    储存温度 -20°C储存,充氩
    分子量 224.21
    分子式 C10H12N2O4
    品牌 Jinpan
    关联CAS 484-78-6
    PubChem CID 89

    Cas(26645-35-2), 伞形毒蕈中的鬼臼酸, Cyclo(Ala-<WBR>2-<WBR>Mercapto-<WBR>Trp-<WBR>4,5-<WBR>Dihydroxy-<WBR>Leu-<WBR>Val-<I>erythro</I>-3-Hydroxy-<SC>D</SC>-Asp-Cys-<I>cis</I>-4-Hydroxy-Pro),Phallacidin from Amanita phalloides,

    发表于由

    伞形毒蕈中的鬼臼酸

    Selective F-actin filament stabilizing agent
    ≥85%

    有货

    Cas(26645-35-2), 伞形毒蕈中的鬼臼酸, Cyclo(Ala-&lt;WBR&gt;2-&lt;WBR&gt;Mercapto-&lt;WBR&gt;Trp-&lt;WBR&gt;4,5-&lt;WBR&gt;Dihydroxy-&lt;WBR&gt;Leu-&lt;WBR&gt;Val-&lt;I&gt;erythro&lt;/I&gt;-3-Hydroxy-&lt;SC&gt;D&lt;/SC&gt;-Asp-Cys-&lt;I&gt;cis&lt;/I&gt;-4-Hydroxy-Pro),Phallacidin from Amanita phalloides,

    CAS编号 26645-35-2 | 品牌：Jinpan
    Phallacidin from Amanita phalloides

    MSDS

    质检证书(CoA)

    相似产品

    • 分子式 C37H50N8N13S
    • 分子量846.904
    • MDL号 MFCD00063359
    • PubChem编号 386391149

    货号 (SKU) 包装规格 是否现货 价格 数量
    P131200-1mg 1mg 期货 Cas(26645-35-2), 伞形毒蕈中的鬼臼酸, Cyclo(Ala-&lt;WBR&gt;2-&lt;WBR&gt;Mercapto-&lt;WBR&gt;Trp-&lt;WBR&gt;4,5-&lt;WBR&gt;Dihydroxy-&lt;WBR&gt;Leu-&lt;WBR&gt;Val-&lt;I&gt;erythro&lt;/I&gt;-3-Hydroxy-&lt;SC&gt;D&lt;/SC&gt;-Asp-Cys-&lt;I&gt;cis&lt;/I&gt;-4-Hydroxy-Pro),Phallacidin from Amanita phalloides,  

    基本信息

    产品名称 伞形毒蕈中的鬼臼酸
    英文名称 Phallacidin from Amanita phalloides
    别名 Cyclo(Ala-2-Mercapto-Trp-4,5-Dihydroxy-Leu-Val-erythro-3-Hydroxy-D-Asp-Cys-cis-4-Hydroxy-Pro)
    英文别名 Cyclo(Ala-2-Mercapto-Trp-4,5-Dihydroxy-Leu-Val-erythro-3-Hydroxy-D-Asp-Cys-cis-4-Hydroxy-Pro)
    应用 Toxin Phallacidin is a weak fluorescent bicyclic peptide probe in aquous solution, Which is isolated from Amanita phalloides mushroom and could be used for blocking F-actin staining by labeled phallotoxins, which promotes actin polymerization.
    规格或纯度 ≥85%
    运输条件 超低温冰袋运输
    生化机理 选择性F-肌动蛋白丝稳定剂。显示与鬼笔环肽类似的生物学作用。防止成对的细丝解离。损害肥大细胞脱粒。

    一般描述

    Toxin Phallacidin is a weak fluorescent bicyclic peptide probe in aquous solution, Which is isolated from Amanita phalloides mushroom and could be used for blocking F-actin staining by labeled phallotoxins, which promotes actin polymerization.

    Toxin Phallacidin is a weak fluorescent bicyclic peptide probe in aquous solution, Which is isolated from Amanita phalloides mushroom and could be used for blocking F-actin staining by labeled phallotoxins, which promotes actin polymerization.

    相关属性

    CAS编号 26645-35-2
    储存温度 -20°C储存
    RTECS GT8943000
    MDL号 MFCD00063359
    分子量 846.904
    分子式 C37H50N8N13S
    品牌 Jinpan
    备注 如果有可能，您尽量在同一天配置溶液，并在当天使用完它。但是，如果您需要预先配制储备溶液，我们建议您将溶液等份保存在-20°C的密封小瓶中。通常，它们最多可以使用一个月。在使用前和打开样品瓶之前，我们建议您让您的产品在室温下平衡至少1小时。有毒，请参阅SDS以获取更多信息。需要更多关于溶解度，用法和处理的建议吗？请访问我们的常见问题（FAQ）页面以获取更多详细信息。
    PubChem CID 386391149

    Spironolactone(Synonyms: 螺内酯; SC9420)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Spironolactone (Synonyms: 螺内酯; SC9420) 纯度: 99.58%

    Spironolactone (SC9420) 是一种具有口服活性醛固酮盐皮质激素受体 (aldosterone mineralocorticoid receptor) 拮抗剂，IC50 值为 24 nM。Spironolactone 也是雄激素受体 (androgen receptor) 拮抗剂，IC50 为 77 nM。Spironolactone 促进足细胞自噬 (autophagy)。

    Spironolactone(Synonyms: 螺内酯; SC9420)

    Spironolactone Chemical Structure

    CAS No. : 52-01-7

    规格 价格 是否有货 数量
    Free Sample (0.1-0.5 mg)   Apply now  
    10 mM * 1 mL in DMSO ￥550 In-stock
    100 mg ￥500 In-stock
    1 g ￥650 In-stock
    5 g ￥1200 In-stock
    10 g   询价  
    50 g   询价  

    * Please select Quantity before adding items.

    Spironolactone 相关产品

    •相关化合物库:

    • Covalent Screening Library Plus
    • Drug Repurposing Compound Library Plus
    • FDA-Approved Drug Library Plus
    • FDA-Approved Drug Library Mini
    • Bioactive Compound Library Plus
    • Metabolism/Protease Compound Library
    • FDA-Approved Drug Library
    • Anti-Cancer Compound Library
    • Autophagy Compound Library
    • Drug Repurposing Compound Library
    • Covalent Screening Library
    • Lipid Compound Library
    • NMPA-Approved Drug Library
    • Orally Active Compound Library
    • FDA Approved & Pharmacopeial Drug Library
    • Drug-Induced Liver Injury (DILI) Compound Library
    • Transcription Factor Targeted Library
    • Food-Sourced Compound Library
    • Tumorigenesis Related Compound Library
    • Rare Diseases Drug Library
    • Children’s Drug Library

    生物活性

    Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].

    Clinical Trial

    分子量

    416.57

    Formula

    C24H32O4S
    CAS 号

    52-01-7
    中文名称

    螺内酯；螺内脂；螺甾内酯
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    In Vitro: 

    DMSO : ≥ 50 mg/mL (120.03 mM)

    H2O : 0.1 mg/mL (0.24 mM; Need ultrasonic)

    * “≥” means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.4006 mL 12.0028 mL 24.0056 mL
    5 mM 0.4801 mL 2.4006 mL 4.8011 mL
    10 mM 0.2401 mL 1.2003 mL 2.4006 mL

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (6.00 mM，饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

      将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

    • 2.

      请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (6.00 mM，饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

      将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
    • 3.

      请依序添加每种溶剂： 10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (6.00 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

    *以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
    参考文献

    • [1]. Kim GK, et al. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012;5(3):37-50.

      [2]. Fagart J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932-29940.

      [3]. Dong D, et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int Urol Nephrol. 2019;51(4):755-764.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Resminostat(Synonyms: RAS2410; 4SC-201)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Resminostat (Synonyms: RAS2410; 4SC-201)

    Resminostat (RAS2410; 4SC-201) 是一种有效的 HDAC1，HHDAC3 和 HDAC6 抑制剂，IC50 值分别为 42.5，50.1，71.8 nM，同时对 HDAC8 有较弱的抑制作用，IC50 值为 877 nM。

    Resminostat(Synonyms: RAS2410; 4SC-201)

    Resminostat Chemical Structure

    CAS No. : 864814-88-0

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Resminostat 的其他形式现货产品:

    Resminostat hydrochloride

    生物活性

    Resminostat (RAS2410; 4SC-201) is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC50 values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC50 of 877 nM.

    IC50 & Target[1]

    HDAC1

    42.5 nM (IC50)

    HDAC3

    50.1 nM (IC50)

    HDAC6

    71.8 nM (IC50)

    HDAC8

    877 nM (IC50)

    体外研究
    (In Vitro)

    Resminostat (RAS2410; 4SC-201; 5 μM) induces histone acetylation in myeloma cells. Resminostat hydrochloride displays a substrate competitive binding mode with a mean Ki value of 27 nM. Resminostat hydrochloride (5 μM) induces histone hyperacetylation in myeloma cells. Resminostat inhibits cell growth, induces apoptosis and inhibits MM cell proliferation. Resminostat (5 μM) also modulates expression of bcl-2 family proteins and inhibits Akt pathway signalling downstream of Akt. Resminostat exerts synergistic activity against myeloma cells when combined with common and new anti-myeloma agents[1].
    Resminostat inhibits cell growth in head and neck squamous cell carcinoma cell lines, with IC50s ranging from 0.775 μM to 1.572 μM (IC50 for SCC25: 0.775 μM; CAL27: 1.572 μM; and FaDu: 0.899 μM). Resminostat (1.25 and 2.5 μM) has a synergistic effect with irradiation on HNSCC cell lines. Resminostat in combination with cisplatin induces a downregulation of survivin. However, Resminostat shows no effect on Mcl-1 and p-AKT expression[2].
    Resminostat reduces viability of HCC cells with the co-treatment of AZD-2014, with IC50s ranging from 0.89 ± 0.12 μM to 0.07 ± 0.01 μM[3].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial

    分子量

    349.40

    Formula

    C16H19N3O4S
    CAS 号

    864814-88-0
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Mandl-Weber S, et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol. 2010 May;149(4):518-28.

      [2]. Enzenhofer E, et al. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines. Head Neck. 2017 May;39(5):900-907.

      [3]. Peng X, et al. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat. Biochem Biophys Res Commun. 2016 Sep 2;477(4):556-562.
    Kinase Assay
    [1]

    Forty microliter enzyme buffer (15 mM Tris HCl pH 8.1, 0.25 mM EDTA, 250 mM NaCl, 10% v:v glycerol) containing HDAC1, 3, 6 or 8 activity, 29 μL enzyme buffer and 1 μL resminostat [HCl] at different concentrations are added to a 96-well microtitre plate and the reaction started by the addition of 30 μL substrate peptide Ac-NH-GGK(Ac)-AMC (HDAC1, 3 and 6 assays, final concentrations 6 μM for HDAC1, 10 μM for HDAC6 and 25 μM for HDAC3/DAD) or Ac-RHK(Ac)K(Ac)-AMC (HDAC8 assay, final concentration 50 μM). After incubation for 180 min (HDAC1, HDAC6, HDAC8) or 120 min (HDAC3) at 30°C, the reaction is terminated by the addition of 25 μL stop solution (50 mM Tris HCl pH 8, 100 mM NaCl, 0.5 mg/mL trypsin and 2 μM trichostatin A [TSA]). After incubation at room temperature for further 40 min, fluorescence is measured using a Wallac Victor2 1420 multilabel counter (extinction 355 nm, emission 460 nm) for quantification of AMC generated by tryptic cleavage of the deacetylated peptide. For the calculation of the 50% inhibitory concentration (IC50) values the fluorescence in wells without test compound (1% DMSO, negative control) is set as 100% enzymatic activity and the fluorescence in wells with 2 μM TSA (positive control) are set at 0% enzymatic activity (background fluorescence substracted)[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    Cell Assay
    [2]

    A CCK-8 cell proliferation assay is used to investigate the antiproliferative effect of resminostat on HNSCC cells. Cells are seeded into 96-well plates at a density of 3 × 105/well. After 24 hours of growth, the cells are treated with resminostat and cisplatin, either alone or in combination and incubated for 72 hours. Untreated cells maintained in RPMI and equal concentrations of dimethylsulfoxide served as control. After 72 hours, cell proliferation is measured by CCK-8. Experiments are carried out in triplicate 3 times[2].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    • [1]. Mandl-Weber S, et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol. 2010 May;149(4):518-28.

      [2]. Enzenhofer E, et al. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines. Head Neck. 2017 May;39(5):900-907.

      [3]. Peng X, et al. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat. Biochem Biophys Res Commun. 2016 Sep 2;477(4):556-562.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    SC209

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    SC209 

    SC209 是个 ADC 细胞毒素，源于专利 WO2021247798, 用于合成抗 EGFR 抗体-药物偶联 ADC。

    SC209

    SC209 Chemical Structure

    CAS No. : 1977557-86-0

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC[1].

    分子量

    488.66

    Formula

    C27H44N4O4
    CAS 号

    1977557-86-0
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Alice Yam, et al. Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof. Patent. WO2021247798.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    SC-43

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    SC-43  纯度: 98.61%

    SC-43，Sorafenib 的衍生物，是一种有效的具有口服活性的 SHP-1 (PTPN6) 激动剂。SC-43 可抑制 STAT3 的磷酸化并诱导细胞凋亡 (apoptosis)，具有抗纤维化和抗癌作用。

    SC-43

    SC-43 Chemical Structure

    CAS No. : 1400989-25-4

    规格 价格 是否有货 数量
    5 mg ￥2500 In-stock
    10 mg ￥3500 In-stock
    25 mg ￥6500 In-stock
    50 mg   询价  
    100 mg   询价  

    * Please select Quantity before adding items.

    SC-43 相关产品

    •相关化合物库:

    • Covalent Screening Library Plus
    • Drug Repurposing Compound Library Plus
    • Clinical Compound Library Plus
    • Bioactive Compound Library Plus
    • Apoptosis Compound Library
    • Immunology/Inflammation Compound Library
    • JAK/STAT Compound Library
    • Kinase Inhibitor Library
    • Metabolism/Protease Compound Library
    • Stem Cell Signaling Compound Library
    • Anti-Cancer Compound Library
    • Clinical Compound Library
    • Small Molecule Immuno-Oncology Compound Library
    • Anti-Aging Compound Library
    • Drug Repurposing Compound Library
    • Covalent Screening Library
    • Differentiation Inducing Compound Library
    • Orally Active Compound Library
    • Anti-Breast Cancer Compound Library
    • Anti-Lung Cancer Compound Library
    • Anti-Pancreatic Cancer Compound Library
    • Anti-Blood Cancer Compound Library
    • Phosphatase Inhibitor Library
    • Transcription Factor Targeted Library
    • Targeted Diversity Library
    • Anti-Liver Cancer Compound Library

    生物活性

    SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects[1][2].

    IC50 & Target[1][2]

    SHP-1

     

    p-STAT3

     

    体外研究
    (In Vitro)

    SC-43 (0-10 μM; 24-72 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment reveals the anti-proliferative effects in cholangiocarcinoma (CCA) cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively[1].
    SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment shows increased sub-G1 cells and G2-M arrest, indicating SC-43 induced differential apoptotic effects in these cell lines[1].
    SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment demonstrates significant increase in cleaved caspase-3 and PARP level[1].
    SC-43 activates SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation. SC-43 augments SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: HuCCT-1, KKU-100, and CGCCA cells
    Concentration: 0 μM, 0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
    Incubation Time: 24 hours, 48 hours, 72 hours
    Result: Revealed the anti-proliferative effects in CCA cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively.

    Cell Cycle Analysis[1]

    Cell Line: HuCCT-1, KKU-100, and CGCCA cells
    Concentration: 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
    Incubation Time: 24 hours
    Result: Showed increased sub-G1 cells and G2-M arrest.

    Western Blot Analysis[1]

    Cell Line: HuCCT-1, KKU-100, and CGCCA cells
    Concentration: 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
    Incubation Time: 24 hours
    Result: Demonstrated significant increase in cleaved caspase-3 and PARP level.

    体内研究
    (In Vivo)

    SC-43 (10-30 mg/kg; oral gavage; daily; for 23 days; male NCr athymic nude mice) treatment exhibits xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male NCr athymic nude mice (5-7 weeks of age) injected with HuCCT-1 cells[1]
    Dosage: 10 mg/kg or 30 mg/kg
    Administration: Oral gavage; daily; for 23 days
    Result: Exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation.

    Clinical Trial

    分子量

    431.80

    Formula

    C21H13ClF3N3O2
    CAS 号

    1400989-25-4
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    In Vitro: 

    DMSO : 250 mg/mL (578.97 mM; Need ultrasonic)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.3159 mL 11.5794 mL 23.1589 mL
    5 mM 0.4632 mL 2.3159 mL 4.6318 mL
    10 mM 0.2316 mL 1.1579 mL 2.3159 mL

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: 2.08 mg/mL (4.82 mM); Suspended solution; Need ultrasonic

      此方案可获得 2.08 mg/mL (4.82 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

      以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

      将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

    • 2.

      请依序添加每种溶剂： 10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution

      此方案可获得 ≥ 2.08 mg/mL (4.82 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

      以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

    *以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
    参考文献

    • [1]. Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089.

      [2]. Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7(1):1728.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务